RU2662713C2 - Пиридопиримидиновое соединение, способ получения, фармацевтическая композиция и применение указанных соединений - Google Patents

Пиридопиримидиновое соединение, способ получения, фармацевтическая композиция и применение указанных соединений Download PDF

Info

Publication number
RU2662713C2
RU2662713C2 RU2015140387A RU2015140387A RU2662713C2 RU 2662713 C2 RU2662713 C2 RU 2662713C2 RU 2015140387 A RU2015140387 A RU 2015140387A RU 2015140387 A RU2015140387 A RU 2015140387A RU 2662713 C2 RU2662713 C2 RU 2662713C2
Authority
RU
Russia
Prior art keywords
oxa
azabicyclo
compound
title compound
alkyl
Prior art date
Application number
RU2015140387A
Other languages
English (en)
Russian (ru)
Other versions
RU2015140387A (ru
Inventor
Цзинкан ШЭНЬ
Кэ ЮЙ
Тао МЭН
Ланьпин МА
Ари Заск
Ланьфан МЭН
Синь Ван
Ии ЧЭНЬ
Original Assignee
Шанхай Инститьют Оф Материа Медика, Чайниз Академи Оф Сайенсиз
Фудань Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шанхай Инститьют Оф Материа Медика, Чайниз Академи Оф Сайенсиз, Фудань Юниверсити filed Critical Шанхай Инститьют Оф Материа Медика, Чайниз Академи Оф Сайенсиз
Publication of RU2015140387A publication Critical patent/RU2015140387A/ru
Application granted granted Critical
Publication of RU2662713C2 publication Critical patent/RU2662713C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2015140387A 2013-03-04 2014-02-28 Пиридопиримидиновое соединение, способ получения, фармацевтическая композиция и применение указанных соединений RU2662713C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310068888.8A CN103588792B (zh) 2013-03-04 2013-03-04 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
CN201310068888.8 2013-03-04
PCT/CN2014/072678 WO2014135028A1 (zh) 2013-03-04 2014-02-28 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Publications (2)

Publication Number Publication Date
RU2015140387A RU2015140387A (ru) 2017-03-30
RU2662713C2 true RU2662713C2 (ru) 2018-07-27

Family

ID=50079144

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015140387A RU2662713C2 (ru) 2013-03-04 2014-02-28 Пиридопиримидиновое соединение, способ получения, фармацевтическая композиция и применение указанных соединений

Country Status (11)

Country Link
US (1) US9796732B2 (enExample)
EP (1) EP2966079B1 (enExample)
JP (1) JP2016510042A (enExample)
CN (1) CN103588792B (enExample)
AU (1) AU2014225155B2 (enExample)
CA (1) CA2903072C (enExample)
DE (1) DE14760712T1 (enExample)
DK (1) DK2966079T3 (enExample)
ES (1) ES2572105T3 (enExample)
RU (1) RU2662713C2 (enExample)
WO (1) WO2014135028A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2019091400A1 (zh) * 2017-11-07 2019-05-16 中国科学院上海药物研究所 吡啶并嘧啶类化合物的盐型和晶型及其制备方法
CN109867667B (zh) * 2017-12-05 2021-06-11 中国药科大学 含有吡啶并嘧啶结构的parp和pi3k双靶点抑制剂
CN113825760B (zh) * 2019-05-06 2022-08-19 南京明德新药研发有限公司 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
WO2021247859A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN115260158A (zh) * 2021-04-30 2022-11-01 上海医药集团股份有限公司 一种靶向蛋白调节剂的化合物及其应用
WO2023018812A1 (en) * 2021-08-10 2023-02-16 Amgen Inc. Heterocyclic compounds and methods of use
JP2024532735A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
US20240417412A1 (en) * 2021-08-10 2024-12-19 Amgen Inc. Heterocyclic compounds and methods of use
JP2025519743A (ja) * 2022-06-15 2025-06-26 ミラティ セラピューティクス， インコーポレイテッド 汎ＫＲａｓ阻害剤のプロドラッグ
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators
CN117586255A (zh) * 2023-09-25 2024-02-23 上海图芃生物科技有限公司 一种口服atp竞争性激酶抑制剂及其合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448109C2 (ru) * 2006-08-08 2012-04-20 Чугаи Сейяку Кабусики Кайся Производное пиримидина в качестве ингибитора pi3k и его применение
CN102887895A (zh) * 2011-07-22 2013-01-23 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
WO2013016999A1 (zh) * 2011-08-04 2013-02-07 江苏豪森药业股份有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
CN103588792A (zh) * 2013-03-04 2014-02-19 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010401A (es) * 2005-02-25 2008-02-19 Kudos Pharm Ltd Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
UA96745C2 (en) * 2005-11-22 2011-12-12 Кудос Фармасьютикалз Лимитед PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
CN101558067B (zh) * 2006-08-23 2014-05-28 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448109C2 (ru) * 2006-08-08 2012-04-20 Чугаи Сейяку Кабусики Кайся Производное пиримидина в качестве ингибитора pi3k и его применение
CN102887895A (zh) * 2011-07-22 2013-01-23 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
WO2013016999A1 (zh) * 2011-08-04 2013-02-07 江苏豪森药业股份有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
CN103588792A (zh) * 2013-03-04 2014-02-19 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Also Published As

Publication number Publication date
US20150368274A1 (en) 2015-12-24
DK2966079T1 (da) 2016-05-17
EP2966079A1 (en) 2016-01-13
EP2966079B1 (en) 2021-11-24
CA2903072C (en) 2019-05-07
CN103588792B (zh) 2016-03-23
HK1217197A1 (en) 2016-12-30
RU2015140387A (ru) 2017-03-30
AU2014225155B2 (en) 2017-11-23
DK2966079T3 (da) 2022-02-14
CA2903072A1 (en) 2014-09-12
AU2014225155A1 (en) 2015-10-15
ES2572105T3 (es) 2022-04-13
ES2572105T1 (es) 2016-05-30
WO2014135028A1 (zh) 2014-09-12
DE14760712T1 (de) 2017-12-14
US9796732B2 (en) 2017-10-24
CN103588792A (zh) 2014-02-19
JP2016510042A (ja) 2016-04-04
EP2966079A4 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
AU2014225155B2 (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
CN113527299B (zh) 一类含氮稠环类化合物、制备方法和用途
RU2747260C2 (ru) Ингибитор рфрф4, способ его получения и его фармацевтическое применение
KR20250070059A (ko) 신규한 테트라헤테로사이클 화합물
CA3177261A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
US20230219946A1 (en) Pyrimidin-4(3h)-one heterocyclic compound, preparation method thereof, and pharmaceutical use thereof
CA3188077A1 (en) Egfr inhibitor, preparation method therefor and application thereof
TWI665203B (zh) 一種氮雜芳基衍生物、其製備方法和在藥學上的應用
JP2018537482A (ja) 抗癌薬として使用される複素環式化合物
KR20190140966A (ko) 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물
BR112016022342B1 (pt) Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos
US11267815B2 (en) Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof
JP2023520595A (ja) ピラゾロピリダジノン化合物、その医薬組成物及びその用途
JP2018135268A (ja) 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
IL310412A (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
Liu et al. Design and synthesis of alkyl substituted pyridino [2, 3-D] pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity
CN113166148B (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
CN115894500B (zh) 一种作为btk激酶抑制剂的化合物及其制备方法与用途
JP2022528437A (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
CN102731525A (zh) 苯并吗啉衍生物
WO2023001061A1 (en) Cdk7 selective inhibitors as anticancer agents
CN114149410B (zh) 吡啶并环类化合物及其制备方法和用途
HK1217197B (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
WO2023187471A1 (en) Heteroaryl derivative compounds, and uses thereof

Legal Events

Date Code Title Description
RH4A Copy of patent granted that was duplicated for the russian federation

Effective date: 20190617

PC41 Official registration of the transfer of exclusive right

Effective date: 20190618